Aurealis Therapeutics Diabetic Foot Ulcer Dose Escalation Patient Trial Low Therapeutic Dose Cohort Completed Successfully, Advances to Medium Therapeutic Dose Group

Basel Switzerland, Kuopio Finland – May 27th, 2021.  Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose […]

Aurealis Therapeutics Novel Chronic Wound Treatment to be Presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease on December 15th, 2020

Basel Switzerland, Kuopio Finland – December 15th, 2020. Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for […]

Aurealis Therapeutics Receives Clinical Trial Application Approval for AUP-16 Diabetic Foot Ulcer Patient Trial

Basel Switzerland, Kuopio Finland – September 27th, 2019. Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans […]

Aurealis Pharma Submitted Clinical Trial Application for First-in-Human Phase 1-2A Clinical Study to German Health Authority Paul-Ehrlich-Institute (PEI)

Press Release Basel Switzerland, Kuopio Finland – October 15th, 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in […]

Aurealis Pharma to Strengthen It´s Board of Directors by Appointing Mr. Iain Buchanan, a Seasoned Biotech and Pharma Industry Executive

Press Release Basel Switzerland, Kuopio Finland – May 22nd 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. […]

Aurealis Pharma To Present at the European Wound Management Association (EWMA) Congress 2018 in Krakow, Poland, May 9th – 11th 2018

Press Release Basel Switzerland, Kuopio Finland – April 30th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company´s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at […]

Aurealis Pharma To Attend The Swiss Biotech Day in Basel, May 3rd 2018

Press Release Basel Switzerland, Kuopio Finland – April 26th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company´s progress at the Swiss Biotech Day in Basel on May 3rd […]

Aurealis Pharma To Present at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich, February 26-27th 2018

Press Release Basel Switzerland, Kuopio Finland – February 19th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on […]

Aurealis Pharma to Present at Swiss Nordic Bio 2018 in Zurich, February 8th 2018

Press Release Basel Switzerland, Kuopio Finland – February 6th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. […]